A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Inclusion Criteria:

• Have an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 or 1 atstudy entry.
• Have a histopathologically or cytologically confirmed diagnosis of gastric orgastroesophageal junction (GEJ) adenocarcinoma.
• Have metastatic disease or locally advanced, unresectable disease.
• Have at least 1 measurable lesion based on Response Evaluation Criteria in SolidTumors (RECIST), Version 1.1.
• Have experienced documented objective radiographic or symptomatic disease progressionduring first-line therapy, or within 4 months after the last dose of first-linetherapy with any platinum/fluoropyrimidine doublet for unresectable or metastaticdisease.
• Have adequate organ function.
• Have urinary protein ≤1+ on dipstick or routine urinalysis.

Exclusion Criteria:

• Have undergone major surgery within 28 days prior to randomization.
• Have received any first-line chemotherapy other than platinum and fluoropyrimidinewith or without anthracycline for advanced gastric or GEJ adenocarcinoma.
• Have received any previous systemic therapy (including investigational agents)targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signalingpathways.
• Have a history of deep vein thrombosis, pulmonary embolism, or any other significantthromboembolism during the 3 months prior to randomization.
• Have significant bleeding disorders, vasculitis, or had a significant bleeding episodefrom the gastrointestinal (GI) tract within 3 months prior to study entry.
• Have a history of GI perforation and/or fistulae within 6 months prior torandomization.
• Have experienced any arterial thromboembolic event within 6 months prior torandomization.
• Have uncontrolled arterial hypertension (systolic blood pressure ≥160 millimeters ofmercury [mmHg] or diastolic blood pressure ≥100 mmHg) despite standard medicalmanagement.
• Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 daysprior to randomization.
• Have a serious illness or medical condition(s).